| Outcome Measures: |
Primary: Beta cell function, The primary objective of this study is to evaluate the action of DPP-IV inhibitors in the prevention of progressive beta cell dysfunction in patients with type 1 diabetes mellitus newly diagnosis ( less than 6 months). It will be measured by the area under the curve of stimulated C peptide within the first 2 hours, C peptide will be measured by the area under the curve of stimulated C peptide within the first 2 hours every 3 months up to one year | Secondary: Immune and inflammatory profile, Inflammatory profile will be measured by some markers such as TNF-alpha, IL-10 and PCR. Immune profile will be obtained by the expression of FOXP3 in both groups., 0,3,6,9,12th months|Secretion of Glucagon and GLP-1, It will be obtained by the measure of glucagon and GLP-1 levels, 0,3,6, 9 and 12months|Glycemic variability, To evaluate the glycemic variability, it will be installed the continuos glucose monitoring system (CGMS) for seven days during the 0, 6 and 12 months., 0, 6 and 12months
|
